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ABSTRACT OF THESIS

REFERENCE POINT INDENTATION OF HUMAN TRABECULAR BONE
TREATED WITH BISPHOSPHONATES FOR VARYING DURATIONS

Reference point indentation (RPI), a novel form of micro-indentation, quantifies
RPI material parameters which correlate with modulus, yield stress, strength, or
toughness. Information linking bisphosphonate treatment length with the material
properties of osteoporotic trabecular bone is needed to improve patient treatment. The
objectives of this study were to: 1) determine if RPI can be used to successfully evaluate
human trabecular bone and if so, determine an optimized test method for using RPI on
trabecular bone, and 2) use this method to determine if any RPI parameters are related to
the duration of bisphosphonate treatment.
Indentation using a 4 N applied force for 5 cycles was determined to be optimal
and used to indent trabecular bone samples from 44 post-menopausal, osteoporotic
female patients treated with bisphosphonates for varying (0.8 to 14 years) durations.
Considering patient age and calcium supplementation use as covariates, six RPI
parameters were significantly (p<0.05) related to BP treatment duration. These results
show that the duration of BP treatment is associated with declining RPI-parameters in
human trabecular bone. Given prior findings linking these RPI parameters with
established material parameters, the present findings suggest that increasing duration of
BP treatment is associated with declining trabecular bone material properties.
KEYWORDS: Reference Point Indentation, bisphosphonates, trabecular bone quality
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1
1.1

Introduction
Bone
Bone is a composite material consisting of mineralized calcium, collagen fibers,

water, and other proteins [1]. This mineralized form of calcium, known as
hydroxyapatite, forms around collagen fibers [1]. Hydroxyapatite crystals grow in the
same orientation as collagen fibers; this contributes to the anisotropic material properties
of bone [1]. Mineralization provides strength and stiffness to bone while collagen
provides flexibility and energy absorption [2].
The relative amounts of mineral and matrix in bone, commonly measured by the
mineral/matrix ratio by using a variety of spectroscopic techniques, has a significant
effect on the bone’s elastic modulus, strength, and toughness (Figure 1.1) [2]. Hypermineralized bone has a higher elastic modulus but reduced toughness [2]. Hypomineralized bone has an increased toughness, a lower modulus, and an intermediate
strength [2].

Figure 1.1 Bone Material Properties with Varying Mineralization
There are two distinctive types of human bone (Figure 1.2). Trabecular bone is a
mesh-like network of thin, calcified tissue strands. Cortical bone is a thick, dense layer
of calcified tissue formed as the outer shell of bone. Only 15-25% of trabecular bone is
calcified while cortical bone is 80-90% calcified [1]. Both types have important load
1

bearing roles, but trabecular bone’s high surface area to volume ratio also serves a
significant role in calcium homeostasis [1].

Figure 1.2 Parts of Bone
1.2

Osteoporosis
Osteoporosis is a bone disease characterized by an above-average increase in

normal bone porosity and a below-average reduction in bone mineral density (BMD) [3].
This disease commonly occurs in post-menopausal Caucasian women due to an estrogendeficient related increase in bone turnover and subsequent decrease in bone
mineralization [4]. Estrogen modulates bone resorption by inducing osteoclast apoptosis
and suppressing osteoclastogenic cytokine production [3]. Lower estrogen levels allow
for increased osteoclast activity which results in increased turnover, hypomineralization,
and mechanically disadvantageous microstructural characteristics such as fewer, thinner,
and less well connected trabeculae (Figure 1.3).
Osteoporosis is diagnosed by measuring lumbar spine and proximal hip BMD
using dual-energy x-ray absorptiometry [5]. The World Health Organization’s criteria for
osteoporosis is that if either hip or spine BMD is more than 2.5 standard deviations below
the gender-specific population average BMD, then the patient is considered osteoporotic
[5].

2

Osteoporosis is a major health problem because of the loss of adequate bone
strength that occurs due to increased porosity, decreased cortical thickness, reduced
trabecular bone structural parameters, and adverse material property changes that
collectively render bone unable to withstand normal physiologically imposed loading.
These structural and compositional changes to bone decrease the extrinsic strength of
bone and have shown a stronger correlation with patient fracture risk than BMD [5] [6]
[7] [8] [9].

Figure 1.3 Healthy vs Osteoporotic Trabecular Bone
1.3

Osteoporosis Prevalence
Fractures are the most serious complication of osteoporosis [10]. Most

osteoporotic fractures occur in the hip or spine and can result in permanent disability or
initiate a sequence of downward-spiraling events that culminate in death [10]. An
increasing number of women with post-menopausal osteoporosis, and the ensuing
compromises to life quality as well as healthcare costs due to osteoporosis-related
fractures, underscore the need for effective treatments. An estimated 10 million
Americans were osteoporotic and an additional 34 million had low bone mass in 2011
[11]. Healthcare costs due to osteoporosis treatment and osteoporotic fractures were
estimated to be $22 billion in 2008 alone [12]. These costs will grow because the number
of Americans with osteoporosis is expected to increase to more than 14 million by 2020
[11] [12] [4].

3

1.4

Treatments for Osteoporosis
Traditional therapies for reducing bone loss and fracture risk attributable to

osteoporosis include monitoring calcium and vitamin D intake and appropriate physical
exercise [13]. A variety of pharmacologic osteoporosis treatments are also routinely
prescribed, but their benefits are under question [14]. Oral bisphosphonates are the most
common pharmacologic treatment for osteoporosis with more than 30 million actively
treated patients worldwide in 2006 alone [15].
1.5

Bisphosphonates
The increase in resorption due to cessation of estrogen production in post-

menopausal osteoporosis can be offset by stimulating bone formation or decreasing bone
resorption. Bisphosphonates suppress bone resorption [16]. Their chemical structure,
which resembles pyrophosphate (Figure 1.4) confers them with a high affinity for
exposed hydroxyapatite crystals in active remodeling sites. Once resorbed by osteoclasts,
bisphosphonates induce osteoclastic apoptosis which in turn results in reduced
osteoclastic activity [17].

Figure 1.4 Bisphosphonate and Pyrophosphate Structure
Extended periods of reduced osteoclast activity resulting from long term
bisphosphonate treatment are known to reduce the rate of bone turnover. Reduced bone
turnover allows old and damaged bone to accumulate [17]. This in turn results in
impaired load-bearing mechanical competence of such bone, and this in turn renders bone
4

more susceptible to fracture than bone with normal turnover [18]. Disagreement exists
regarding the consequences of increased fracture risk and the benefits of long-term
bisphosphonate treatment. Some believe the estimated 1 in 1,000 risk of long-term
bisphosphonate related atypical femoral fractures is overshadowed by the overall fracture
reducing benefits of the bisphosphonates [19]. Others speculate that 100 osteoporosisrelated fractures are prevented for every atypical fracture related to bisphosphonate
treatment [20]. Some suggest discontinuing bisphosphonate use if bone mineral density
levels are adequate [20].
1.6

Material Property Assessment
There are well established methods for determining the material properties of bone

[21]. Macroscopic load to failure testing is the current gold standard for quantifying the
bone material properties. Surrogate testing methods with technological advantages have
been created and among these is nanoindentation, a spin-off of Atomic Force
Microscopy. This method has recently emerged as a useful technique for non-destructive
measurement of Young’s modulus and hardness of bone with great spatial resolution
[21].
The applied force and resulting displacements obtained from nanoindentation
testing are recorded from a diamond indenter tip as it is forcibly pressed deeper into a
polished flat surface of the material being tested [21]. A portion of the forcedisplacement unloading slope (Figure 1.5) is used to calculate material modulus by using
a model developed by Oliver and Pharr and as quantified in
Equation 1 and Equation 2 [22] [23].
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Figure 1.5 Ideal Nanoindentation Load-Displacement Cycle
These calculations assume a flat, polished indenting surface, zero frictional forces,
and a material that is linear elastic and incompressible [24] [22]. Calculation of the
projected contact area between the probe and indentation surface is based upon the
known geometry of the probe and its penetration depth.
Equation 1: Nanoindentation Reduced Modulus

Er:
hc, β:
Ap(hc):
S:

Reduced modulus
Geometric constants
Projected area of the indentation at the contact depth
Stiffness of contact (unloading slope)
Equation 2: Nanoindentation Material Modulus

Ei:
Es:
νi:
νs:

Known indentation probe modulus
Modulus of material
Poisson’s ratio of probe
Poisson’s ratio of material
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Nanoindentation indent widths can range from 10 to 1000 nanometers which allows
a high degree of location specificity. Material properties of bone measured by
nanoindentation vary between individuals and specific bones [25] [26]. Variability is
also dependent upon indent location and lamellar orientation within the same bone [27]
[28] [29].
1.7

Reference Point Indentation
Microindentation techniques load materials in a similar manner to nanoindentation

but utilizes larger probe dimensions, greater penetration depths (30-200 microns vs. 101000 nanometers), and greater indentation widths (Figure 1.6). Because of the greater
size microindentation probes, this technique is influenced by bone porosity, multiple
lamellae layers, interfaces between structural units, and microdamage [30].

Figure 1.6: Nanoindentation vs RPI Depth in a Trabeculum
RPI instrumentation systems typically include a measurement head unit,
measurement stand, and probe assembly (Figure 1.7). The measurement head unit
contains a force generator, force sensor, and displacement sensor. The measurement
stand enables accurate probe-on-sample positioning by using via an XY translational
table to place the indentation probe tip at the desired location. The probe assembly
consists of two coaxial components; an indenting test probe that moves coaxially within a
reference probe (Figure 1.8). The test probe consists of a 375 micron diameter rod with a
90 degree coned tip having a radius of less than 5 microns [31]. The reference probe
consists of a hollow tube (fabricated from a modified hypodermic needle) that coaxially
contains the test probe.

7

Figure 1.7 Reference Point Indentation Device

Figure 1.8 Reference Point Indentation Probe Illustration
Reference point indentation begins by first placing the reference probe on the
surface of the material to be indented. This locates the site of the test by constraining the
test probe from lateral motion across the surface during the indentation process. The test
probe repetitively indents the material with a specified number of cyclic indents. Each
indentation involves slightly deeper penetration of the probe in the test surface compared
8

to the previous indent. Transducers in the measurement head record test probe
displacement and indentation force throughout this process as the tip of the probe moves
within and relative to the surface of the material being indented.
Based upon this set of repetitive indentations and continuous measurement of
probe force and accompanying displacement, the test system calculates nine material
property relevant parameters based on the time dependent force versus indentation probe
displacement. These nine material property relevant parameters are:
1. First cycle indentation distance (ID1st).
2. Total indentation distance (TID)
3. Indentation distance increase (IDI)
4. First cycle creep indentation distance (CID1st)
5. Average creep indentation distance (AvgCID)
6. Average loading slope (AvgLS)
7. Average unloading slope (AvgUS)
8. First cycle unloading slope (US1st)
9. Energy dissipation (ED)

9

1.7.1

Indentation Depth Parameters (Parameters 1-5)
Five of these parameters (ID1st, TID, IDI, CID1st, and AvgCID) are obtained from

test probe force and displacement data (Figure 1.9).
Table 1.1 RPI Parameters
Parameter

How Derived

ID1st

Probe
displacement

TID

Probe
displacement

IDI

Probe
displacement

CID1st
AvgCID
AvgLS

AvgUS

US1st

ED

Probe
displacement
Probe
displacement
Ratio of probe
displacement
and force
Ratio of probe
displacement
and force
Ratio of probe
displacement
and force
Integration of
forcedisplacement
curve

How Calculated
After first
indentation
cycle
After last
indentation
cycle
Difference
between first
and last
indentation
cycle
During constant
load
During constant
load

Relevance
Reflects
material
hardness
resist crack
initiation and
propagation

References

Strength and
toughness

[30] [33] [34]
[35] [36] [37]

Toughness

[38]

Toughness

[38]

During loading

resistance to
plastic
deformation

[36]

During
unloading

Strength and
toughness

[35]

During
unloading

Strength and
toughness

[35]

Over the entire
loading cycle

Toughness

[38]

[35] [36]

[32] [33]

ID1st is a measure of test probe penetration depth after the first indentation cycle
and has been associated with material hardness [35] [36]. TID is the total displacement
of the probe into the substrate after all loading cycles and is related to bone’s ability to
resist crack initiation and propagation [32] [33]. Changes in TID have been associated
with changes in: rat vertebrae compressive strength and toughness as well as yield stress
10

and strength in three-point bending of human femora [35] [33]. IDI is the difference
between the initial and final cycle indentation depths. Changes in IDI have been
associated with changes in: a) strength and toughness in three point bending of rat
femurs, canine ribs, and human femora, and b) strength and toughness in axial
compression of rat vertebrae [30] [33] [34] [35] [36] [37].
Reference point indentation also quantifies two material creep-relevant parameters
(CID1st and AvgCID) by recording probe displacement while a constant force is
maintained on the probe (Figure 1.9). CID1st is the probe displacement during the first
cycle of constant load. AvgCID is the average of probe displacement of all constant load
cycles. Changes in these creep parameters have been inversely associated with material
toughness [38].

Figure 1.9 Indentation Depth Measurements
1.7.2

Loading/Unloading Slope Parameters (Parameters 6-8)
Three parameters (AvgLS, AvgUS, and US1st) consider the force-displacement

slope during loading and unloading of the indentation probe force (Figure 1.10). AvgUS
considers the ratio of material strain to test probe force during all indentation cycle while
indentation force is decreasing. AvgUS has been associated with strength and toughness
as measured by dynamic compression testing [35]. US1st considers the ratio of material
11

strain to test probe force during the first indentation cycle. Although all of these
unloading slope measurements are not a direct measurement of the sample’s Young’s
modulus, they are an indication of Young’s modulus [35]. The average unloading slope
parameter is able to detect differences between longitudinal and transverse indentations
of cortical bone. [36]. AvgLS is similar to average unloading slope but considers the
time periods when the test probe force is increasing. It is related to bone’s resistance to
plastic deformation [36]. AvgLS, AvgUS, and US1st values are calculated (Equations 35) using values from the force-displacement graph (Figure 1.10).

Equation 3: AvgLS Calculation

Equation 4: AvgUS Calculation

Equation 5: US1st Calculation
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Figure 1.10 Loading and Unloading Slope of Example Materials A and B
1.7.3

Energy Dissipation Parameter (Parameter 9)

Unrecoverable material deformation after indentation is reflected by the energy
dissipation (ED) parameter. This parameter is defined by the area bounded by the load
and unload curve of the force-displacement relationship (Figure 1.10). This parameter is
related to material toughness [33].

Figure 1.11 Reference Point Indentation Dissipated Energy
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1.8

RPI Testing of Bisphosphonate Treated Cortical Bone
Several studies have investigated the effects of bisphosphonate treatment and the

resulting changes in cortical bone RPI parameters. Arefa et al. treated beagles with
raloxifene for 6 months to measure changes in their bone material properties [34]. RPI
testing of the anterior tibial mid shaft surfaces of these beagles was performed using 12
beagles while another 12 were controls that received oral saline only. IDI and ED were
approximately 15% less in the treated beagles compared to the control beagles [34]. A
related study by Gallant et al. found that healthy beagles treated with bisphosphonates for
three years resulted in an approximate 17% increase in cortical rib IDI compared to
untreated control beagles [35]. The observed differences in IDI parameters between
these two studies may be due to the difference (6 months compared to 3 years) in
treatment duration.
Human anterior mid-tibial cortical surfaces were indented by Güerri-Fernández et
al. using an early prototype reference point indentation system to investigate differences
between patients with: a) atypical femoral fractures treated with bisphosphonates (AFF),
b) typical osteoporotic fractures and no BP treatment, c) no fractures with long-term (5 to
12 years) bisphosphonate use, and d) no fractures and no treatment [30]. TID and IDI in
patients with atypical femoral fractures treated with bisphosphonates were approximately
25% greater compared to osteoporotic patients with no fractures and no treatment [30].
1.9

RPI and Trabecular Bone
All previous studies that applied microindentation test methods to osseous tissue

examined cortical bone exclusively. Application of RPI to trabecular bone is technically
challenging due to: limited available surface area of trabeculae relative to probe size,
depth of indentation relative to trabeculae depth, and accuracy/precision of indentation
probe tip placement on trabeculae. If RPI can be used to quantify the indentation relevant
material parameters of trabecular human bone, then additional studies must be conducted
to determine accuracy and precision within trabeculae and subjects, as well as intra and
inter observer variability.

14

1.10 Objectives
The objectives of this study were to: 1) determine if RPI use for trabecular bone is
feasible and if so, to then determine an optimized test method for using RPI on trabecular
bone, and 2) use this optimized method for quantifying the RPI parameters of human
trabecular bone treated with BPs for varying durations.
2

Microindentation Testing of Human Trabecular Bone

2.1

Objective
The previously noted challenges attending application of RPI to trabecular bone

formed the basis for the first portion of the present research effort. Use of RPI in
trabecular bone must be proven feasible by determining whether accurate and precise
probe placement and RPI measurements can be made in this bone compartment.
2.2
2.2.1

Theoretical Indentation Depth and Separation Determination
Strain Field Propagation
The purpose of the finite element model was twofold; to determine if the strain and

stress field produced by an indentation depth of 50 microns could be confined to the
dimensions of a trabeculum and to determine the minimum separation between indents
without strain field interference. The volume of trabecular bone permanently altered by
an indentation using RPI is primarily influenced by the probe size and indentation force.
While probe size is fixed, increasing probe indentation force increases the indentation
depth. Increasing the indentation depth reduces measurement uncertainty due to the
device’s linear transducer measurement resolution which rounds to the nearest micron.
Therefore, a measured 50 micron indentation depth could actually be between 49.5
microns and 50.49̅ microns. Since all trabecular bone samples are embedded in PMMA,
an indent larger than the trabecular width or depth would deform the PMMA mounting
material and result in testing material that was not 100% trabecular bone. The
deformation size produced by an indentation can be estimated using finite element
modeling to determine an optimal indentation force.
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2.2.2

Indentation Separation
Minimizing indent separation distance increases the total number of indents

possible in a sample of limited trabecular surface area. Indent separation distance must be
large enough to avoid strain field interaction between adjacent indents. Identification of
this minimal indentation separation distance can be estimated using finite element
analysis.
2.2.3

Finite element method
Deformation of a simple structure with known material properties caused by an

applied force can be calculated using standard deformable solid body mechanics. Finite
element analysis allows larger, more complex structures to be analyzed in the same
manner by conjoining a finite number of simple shapes together. Each simple shape,
deemed an element, can be represented by a line, triangle, quadrilateral, or any shape
solvable with partial differential equations. The deformable solid calculations for these
numerous elements can be solved simultaneously to determine theoretical stress and
strain within a complex structure given assumed boundary conditions, deformations, and
forces acting upon the structure. This method of using numerous smaller elements to
analyze a complex deformable solid structure was originally developed by Ray W.
Clough in 1960 and is known as finite element analysis [39].
2.2.4

Model Geometry, Constraints, and Properties
The finite element model for trabecular bone indentation was based upon a single

body having linear elastic geometry. The indentation was represented by a force
distribution. The trabeculum to be indented was assumed to be a simple semi-cylinder
with the center of indentation placed along the cylindrical axis. Three planes of
symmetry were used in this model (Figure 2.1). The first plane of symmetry was normal
to the cylindrical axis and placed at varying distances from the center point of
indentation. The second plane of symmetry was normal to the cylindrical axis and passed
through the center point of indentation. The separation between the first and second
symmetry planes represented half of the theoretical separation distance between indents.
The third plane of symmetry was parallel to the cylindrical axis and perpendicular to the
indentation surface. This plane of symmetry transforms the semi-cylinder into a quarter16

cylinder. The planes of symmetry are constrained in both X and Z directions. The
remaining circumferential surface of the cylinder, representing the boundary with
PMMA, was assumed to be a fixed support. The orientations of the three planes are
shown (Figure 2.1). The elastic modulus and Poisson’s ratio values used to represent
trabecular bone were assumed to be 10 GPa and 0.3 [40]. Although bone is a viscoelastic
material, for purposes of this model it was assumed that bone was linearly elastic,
isotropic, and homogeneously mineralized.

Figure 2.1 ANSYS Model Symmetry Planes

Figure 2.2 ANSYS Variable Load Pressure Indentation Model
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2.2.5

Material Properties and Indentation Force Modeling
The indentation force used in the model was represented by a triangularly shaped

non-uniform pressure distribution normal to the indentation surface and axisymmetric to
the center point of indentation (Figure 2.2). The length of the non-uniform pressure was
50 microns based on a 90 degree indentation probe tip angle and a target indentation
depth of 50 microns. Therefore, the pressure at the edge of the resulting 100 micron
diameter indent was zero and the pressure at the center of the indent was determined by
trial and error until the largest deformation in the body was approximately 50 microns.

Figure 2.3 Strain Plot of 200 micron Indent Separation
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2.2.6

Theoretical Results
The FEA model of probe indentation into bone was solved using 11 varying center-

to center probe indentation distances ranging from 250 to 125 microns. Total
deformation of the structure resulting from the controlled pressure distribution was
calculated. The largest deformation determined the indentation depth and this value was
plotted versus the separation between indents (Figure 2.4). This plot shows that
indentation depth increases exponentially when center-to-center indentation distances
decrease and become less than 175 microns.

Indentation depth vs separation
51.75

Depth (microns)

51.5

51.25
51
50.75
50.5
50.25

50
100

120

140

160

180

200

220

Separation (microns)

Figure 2.4 Indentation Depth versus Indent Separation
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2.2.7

Theoretical Discussion
The strain and stress fields propagated in the trabeculum without interacting with

the lower or edge boundary conditions for the assumed trabeculae size of 280 microns.
Figure 2.3 shows an indentation depth of 50 microns will not interact with PMMA
considering the dimensions of this trabecular bone model.
The device’s transducer measures to the nearest micron. Therefore if strain field
interference between two adjacent indents results in a depth variation of less than 1
micron the device will not detect it. This occurs if the center-to-center indentation
distances are greater than 175 microns. The finite element model used assumed that a 4
Newton indentation force was used to produce the indentations. Four N of indentation
force in preliminary experimental testing using actual human trabecular bone samples
was the maximum observed indentation force which showed minimal risk for penetrating
a trabeculum.

Figure 2.5 Indentation Sizes of Different Protocols
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The limitations of the FEA model used were attributable to assumptions made
regarding material properties, trabecular shape and size, and indentation force. Although
the shape of the modelled trabeculum does not affect propagation of the strain field
caused by the indentation, provided that the strain field does not extend to the surface of
the trabeculum. A vertical axisymmetric pressure distribution does consider force vectors
and shear forces associated with indentation. The shape and size of the indent and
resulting strain field are comparable to the experimental microindentation when only
considering the effects of indentation separation and depth. These results were verified
by the low coefficient of variation seen between adjacent indents separated by 200
microns in the following section (2.3).
2.3
2.3.1

Experimental Indentation Protocol and Sample Size Determination
Maximizing Sample Size
Results of the FEA model show that a force of 4 N and a separation of 175

microns were optimal for reference point indentation of trabecular human bone. Next,
the sources of experimental variance needed to be identified and the contributions from
each estimated so that an optimal RPI testing protocol could be developed. This protocol
needed to be as sensitive as possible to allow the relationship between BP treatment
duration and one or more RPI parameters to be elucidated, if such relationships do in fact
exist. Specific testing parameters targeted for optimization included the: number of
indents per sample, the number of trabeculae tested per sample, and the number of
samples. A balance needed to be achieved for the total number of indents per sample so
that random error could be minimized while maximizing the number of samples with
adequate trabecular surface area for testing. The estimated random error of each possible
protocol can be used to determine the optimal indent quantity per location within a
sample. The objective of this experimental portion of the study was to determine which
protocol had the least variance.
2.3.2

Methods
Two groups (pre and post-menopausal) of four homogenous ex vivo trabecular

bone samples from otherwise identical pre and post-menopausal women were obtained.
Samples consisted of low turnover bone from osteoporotic Caucasian female patients
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with no history of: bisphosphonate treatment, hormone therapy, cancer, recent smoking,
steroid use, chronic kidney disease, or diabetes. 55 bone samples matching these criteria
were obtained. These samples were prepared for RPI testing and then indented three
times on each of 3 trabeculum per sample for a total of nine indentations per bone
sample.
The results were used to calculate the observed variance between: a) bone samples
(σb2), b) trabeculae within a bone sample (σt2), and c) indents within a trabeculum (σi2)
for each RPI parameter by analyzing the variance within each level of the hierarchical
design. The observed variances were used to estimate the variance for other candidate
indentation protocols using Equation 6.
Equation 6: Estimated Coefficient of Variation for Candidate Protocols
𝐶𝑉𝑋 =

𝜎𝐵
𝑁𝐵 𝑋

+

𝜎𝑇
𝑁𝐵 𝑁𝑇 𝑋

+

𝜎𝐼
𝑁𝐵 𝑁𝑇 𝑁𝐼 𝑋

∗ 100

Where
𝑋 = Output parameter mean
σ = Observed variance between indents (𝜎𝐼 ), trabeculae(𝜎𝑇 ), and samples (𝜎𝐵 )
N = Number of indents (𝑁𝐼 ), trabeculae (𝑁𝑇 ), and biopsies (𝑁𝐵 ) considered
Coefficients of variation for each RPI parameter were averaged so that each
protocol and sample size could be represented by a single coefficient of variance. There
were a total of 14 bone samples treated 10 or more years with bisphosphonates
constituted the fewest number of samples. This important subset of the available samples
formed the basis for determining the experiment that maximized the information from
these samples and minimized the variance in observed RPI parameters. These samples
were collected and visually examined for available cross sectional trabecular area. Each
exposed trabeculum on each of these 14 samples was estimated for the number of times it
could be indented assuming 200 microns of indentation separation and 4 N of indentation
force. Quantification of the area in each sample, in units of indentation quantity, allows a
maximum number of available samples to be identified given a specific indentation
protocol. The number of trabeculae in each sample that can be indented given a specific
number of indents is shown (Table 2.1).
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2.3.3

Experimental Results
All candidate indentation protocols, based upon indent allocation and sample size,

were represented by a single coefficient of variation for each parameter. The calculated
coefficient of variances for 5 to 14 bone samples, 1 to 5 trabeculae per sample, and 1 to 4
indents per trabeculum were plotted MATLAB. Figure 2.6 shows the coefficient of
variance for the total indentation depth parameter for each of the combinations. Each
possible candidate protocol and its corresponding average coefficient of variation was
compiled and ranked by variance in

Table 2.2.

Figure 2.6 Total Indentation Depth Predicted Coefficient of Variation
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Table 2.1 Possible Indentations in 10+ Year Treated Samples
# of Indents per Trab
Bone Sample ID Number 4
3
2
1
B05411
0
1
2
3
B07507
0
2
3
4
B10710
2
2
5
5
B03911
0
2
3
3
B05610
1
2
6
6
B02912
0
1
2
2
# of Trab
B04208
0
1
3
3
B09111
0
2
5
6
B04110
1
3
5
5
B05310
1
3
7
7
B06110
1
2
4
4
B03109
2
4
6
6
B04612
0
0
1
1
B07010
1
1
4
4

Table 2.2 Possible Protocols, Maximum Sample Size, and Coefficient of Variation
Possible Protocol and Resulting Variation
Trab
Indents
Samples
Avg C of V
2
2
13
0.0317
2
1
13
0.0326
3
2
11
0.0332
1
2
14
0.0336
1
3
13
0.0343
1
1
14
0.0351
4
1
9
0.0366
2
3
9
0.0377
4
2
8
0.0382
5
2
6
0.0436
5
1
6
0.0442
1
4
7
0.0464
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2.3.4

Experimental Discussion
The largest contributor to the observed variance was the number of indented bone

samples. The second largest contributor to the observed variance was the number of
trabeculae indented followed last by the number of indentations on each trabeculum. The
degree of contribution for each protocol variable is evident in the three-dimensional plot
in Figure 2.6. Increasing the number of indented samples is the most efficient means of
decreasing random error.
Variance between samples outweighs variance within the sample because the
proximity of indents in a single sample. Indents within a sample are no more than a few
centimeters apart. Indents within a trabeculum are measured to a consistent 200 microns
apart. Although material properties of bone have been shown to vary in different
locations of the same bone [41], they are more likely to vary between patients than within
a sample. Bone homogenization due to bisphosphonate treatment may reduce this
variance between treated patients [4] [41].
2.4

Conclusion
Reference point indentation using two indents per trabeculae and two trabeculae

per bone sample offered the lowest calculated CV and was therefore selected for use
based upon the samples available for examining the relationship between bisphosphonate
treatment duration and the RPI parameters. Finite element modeling determined minimal
indentation separation to be 175 microns to avoid detectable strain field interaction.
Indentations depths of 50 microns showed no interaction upon the trabecular boundary
with PMMA.
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3

RPI of Trabecular Bone with Varying Bisphosphonate Treatment Duration

3.1

Objectives
The objective of this study is to determine if any RPI parameters (refer to the list

cited in section 1.7) are related to the duration of bisphosphonate treatment in human
trabecular bone by implementing the previously established RPI testing procedure.
3.2
3.2.1

Methods
Study Design
The dependent variable in this cross sectional study was an individual’s duration

of bisphosphonate treatment in years. The independent variables were the RPI output
parameters (section 1.7). The sample size was expected to be approximately 40.
Analysis of variance was used to relate each RPI parameter with BP treatment duration.
Multiple regression analysis was used to consider the following covariates: age, bone
volume per total volume, bone mineral density, hormone therapy, fracture history,
exercise, calcium supplement use, and prescription vitamin D use. This study conforms
to the Declaration of Helsinki and was approved by the University of Kentucky IRB.
3.2.2

Inclusion Criteria
Bone samples were obtained from anterior iliac crest biopsies taken from

osteoporotic post-menopausal Caucasian female patients between 41-87 years of age who
had low bone turnover. These bone samples were catalogued in the Kentucky Bone
Registry maintained by the University of Kentucky’s Division of Nephrology and
identified by electronic database.
3.2.3

Exclusion Criteria
Samples excluded from patients with: osteogenesis imperfecta, osteomalacia, any

genetic bone disease, hyperparathyroid disease, chronic kidney disease, Paget’s disease
of bone, a history of drug or alcohol abuse, a history of smoking, SERM use, steroid use,
teriparatide treatment, and any medications/disease known to alter bone metabolism.
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3.2.4

Procedure
Bone samples in the registry were previously embedded in poly methyl

methacrylate (PMMA) for processing and preservation. Embedded bone samples that
were enrolled in this study were cut to show trabecular cross sections. Each cross
sectioned surface was ground and polished flat and smooth using abrasive silicon carbide
papers of decreasing grit size (ending in 1200 grit). A final polish was achieved using a
rotating micro cloth wetted with deionized water and suspended diamond particles (0.3μm grit size and then 0.05-μm grit size). Samples were placed in an ultrasonic water bath
for 10 minutes to remove grinding and polishing debris.
Each sample was clamped in a vice with its polished surface oriented horizontally
(Figure 3.1). The sample was visually accessed under a Bausch & Lomb Stereozoom 4
stereo microscope. Differentiating areas of PMMA and exposed bone on the surface of
each sample was difficult due to the polished surface and lack of color contrast. The
distinction could only be made when a directional light source was reflected off the
surface to the observer to better reveal surface texture. The smooth, polished PMMA
surface appears glossier than texturized bone tissue as shown in Figure 3.2.

Figure 3.1 Trabecular Bone Sample Secured in Vice with V-block Insert
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Figure 3.2 Trabeculae Identification and Probe Placement
Placing ink dots on potential indentation sites allowed for more accurate aiming
of the probe once the sample was in the machine. While viewed through the stereo
microscope (Figure 3.2) ink dots of approximately 80 microns diameter were placed on
trabecular areas of sufficient size to accommodate two indentations set 200 microns or
more apart. Two trabeculae from all trabeculae identified as having sufficient available
test surface area were chosen for indentation at random using a coin flip. The mounted
(V-block, Figure 3.1) sample was then placed onto the horizontal test stage of the RPI
instrument and rotated so that an imaginary line between two potential indents aligned
with the translational table’s X or Y axis (Figure 3.3).

Figure 3.3 X Y Translation Table for Measuring Indent Separation
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The RPI head unit was positioned over and lowered onto the sample surface until
the RPI device’s scale registered a preload of 530-570 grams. A maximum indentation
force of 4 N was used in this study. Preloading the sample insured that the reference
probe maintained its XY position on the sample surface during indentation. After
indentation, the head unit and indentation probe were raised off the sample surface and
the sample was moved 200 microns to the next indentation site using a single axis of the
XY translational table. The resulting indents are shown in Figure 3.4.

Figure 3.4 Probe Placement and Resulting Indents
After translating the sample 200 microns the head unit was lowered to a preload
of 530-570 grams and the second indentation was made. The procedure was repeated to
indent the second trabeculum to complete a total of four indents in each sample.
Indentation validity was defined by the indentation depth, shape of the force vs.
displacement graph, and visual inspection of the indent. Visual PMMA deformation
around an indent or a hole in the center of the indented bone tissue is the best indicator of
an invalid indent (Figure 3.5 Characteristics of an Invalid Indent Results
Results
Unusually high indentation depths and low loading slopes displayed by the device
software (measured values at least 30% different than the average value recorded in each
sample) may indicate that an indentation involved both PMMA and bone. This can occur
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if an indent is too close to the edge of a trabeculum or if a trabeculum has insufficient
depth or width to sustain an indentation. Invalid indents were noted in the software and
excluded from data analysis.

Figure 3.5 Characteristics of an Invalid Indent Results
3.3

Results
Of the 58 samples meeting the inclusion criteria, but not the exclusion criteria, 44

were enrolled in the present study and successfully indented. Samples not indented had
inadequate exposed surface area or failed accommodate the selected indentation protocol
given the previously discussed validity criteria. Samples from bisphosphonate treated
subjects (0.3 to 14 years) and five samples from untreated osteoporotic subjects were
indented.
Indentation distance increase (IDI, section 1.7) (p=0.012), first cycle unloading slope
(US1st) (p=0.048), and average unloading slope (AvgUS) (p=0.029) were significantly
correlated with bisphosphonate treatment duration. When considering the covariates age
and calcium supplementation use, indentation distance increase (IDI) (p=0.001), total
indentation depth (TID) (p=0.049), energy dissipated (ED) (p=0.042), first cycle
unloading slope (US1st) (p=0.028), average unloading slope (AvgUS) (p=0.012), and
average loading slope (AvgLS) (p=0.049) significantly correlated with bisphosphonate
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treatment duration. These RPI parameters were optimally related to subject age, calcium
supplementation use, and bisphosphonate treatment duration using Equation 7.
Equation 7: Multivariate Regression Equation

Where,
𝛽0:
𝛽𝐴 , 𝛽𝐶 , 𝛽𝐷 :
Age:
Calcium:
BP Duration:

RPI Parameter Intercept
Coefficient for Age, Calcium Use, and Treatment Duration
Age of Patient in Years
Binary Value for Patient Calcium Supplementation
BP Treatment Duration in Years

None of the other 9 RPI parameters (CID, CID1st, and ID1st) were related to
bisphosphonate treatment duration despite consideration of all listed covariates. The
multiple regression equation coefficients for the 6 correlated RPI parameters are shown
(Table 3.1). Linear regression plots for each of these 6 equations are provided (Figure
3.6-Figure 3.11).
Table 3.1 Multiple Regression Equation Coefficients
IDI

TID

ED

US1st

AvgUS

AvgLS

𝑏0

4.9070

44.092

11.38855

0.29434

0.29172

0.20779

𝑏𝐴

-0.00979

-0.03811

-0.01809

0.00026

0.00035

0.00021

𝑏𝐶

-0.45104

-1.23064

-0.81775

0.00764

0.01001

0.00550

𝑏𝐷

0.04678

0.10300

0.10206

-0.00136

-0.00158

-0.00080

Table 3.2: p Values for Regression Equation Coefficients
IDI

TID

ED

US1st

AvgUS

AvgLS

𝑏𝐴

NS

NS

NS

NS

NS

NS

𝑏𝐶

0.0017

0.0188

NS

NS

NS

NS

𝑏𝐷

0.0013

0.0490

0.0423

0.0284

0.0118

0.0485
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Figure 3.6 Indentation Distance Increase (IDI, µm) vs Bisphosphonate Treatment
Duration (dur, years) (p=0.0115) (R2=0.34)

Figure 3.7 Total Indentation Depth (TID, µm) vs Bisphosphonate Treatment Duration
(dur, years) (NS) (R2=0.19)
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Figure 3.8 Energy Dissipated (ED) vs Bisphosphonate Treatment Duration (dur, years)
(NS) (R2=0.14)

Figure 3.9 1st Cycle Unloading Slope (US1st) vs Bisphosphonate Treatment Duration
(dur, years) (p=0.0481) (R2=0.13)
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Figure 3.10 Average Unloading Slope (AvgUS) vs Bisphosphonate Treatment Duration
(dur, years) (p=0.0286) (R2=0.18)

Figure 3.11 Average Loading Slope (AvgLS) vs Bisphosphonate Treatment Duration
(dur, years) (NS) (R2=0.12)
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3.3.1

Calcium Supplement Usage
Subjects who did not report using calcium supplementation were found to follow a

significantly higher regression slope than those not taking a supplement. This difference
between regression slopes was found by testing the interactive relationship between
variables of calcium supplementation and treatment duration within the multivariate
regression models for TID and IDI. Figure 3.12 and Figure 3.13 show the differences in
regression slope with (35 patients) and without (7 patients) calcium supplementation for
TID and IDI.

Figure 3.12 IDI vs Treatment Duration Considering Calcium Usage
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Figure 3.13 TID vs Treatment Duration Considering Calcium Usage

3.4

Discussion
RPI parameters can be sorted into to two categories based upon how the parameter

is calculated. All RPI parameters are calculated by measuring either test probe
displacement (indentation depth parameters) or the relationship between force and test
probe displacement (loading/unloading slope parameters). Both of these categories
include RPI parameters which were shown by the results of the present study to be
significantly correlated with bisphosphonate treatment duration. Because these
parameters and have also been related to established material properties, the results of the
present study provide evidence that the material properties of trabecular bone are related
to bisphosphonate treatment duration. The three indentation depth parameters correlated
positively with bisphosphonate treatment length while the three loading/unloading slope
parameters negatively correlated with bisphosphonate treatment length. An RPI
parameter’s significance with bisphosphonate treatment length was found to be generally
affected by which indentation cycle(s) were used in the calculation of the RPI parameter.
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3.4.1

Indentation Depth with Increasing Treatment Duration
The indentation distance between the first indentation cycle and last indentation

cycle increased with increasing bisphosphonate treatment duration. A similar trend was
seen in outputs of ED and TID. ED is a function of TID and the force applied over time.
The force produced by the indentation probe is consistent for each indentation, therefore
ED is directly related to TID due to ED’s calculation method. This explains similar ED
and TID p-values (p=0.049 and 0.049 respectively) and multiple regression coefficients
seen in .
Table 3.1.
First cycle indentation depth was the only indentation depth parameter that was
unrelated to bisphosphonate treatment duration. The particular locations at which an
indent was placed may contain varying amounts of physical imperfections such as
microcracks or surface imperfections. The 1st cycle indentation depth deforms the most
bone volume. The calculations for ED and TID take the 1st cycle indentation depth
measurement into account. Physical material imperfections may have contributed to the
higher data variability seen in ED (p=0.049) and TID (p=0.049) compared to another
indentation depth parameter that doesn’t take 1st cycle indentation depth into account
(p=0.01 for IDI). Three of the four RPI indentation parameters (TID, ID1st, IDI, and ED)
each calculated using indentation depth, showed significant positive relationships with
bisphosphonate treatment duration. These parameters reflect changes in the material
properties of bone associated with varying bisphosphonate treatment duration.

3.4.2

Indentation Depth and Material Properties
IDI has been shown in other studies to be inversely proportional to yield stress,

strength, and toughness as measured by traditional destructive mechanical tests [37] [30]
[35] [36] [33]. Güerri-Fernández et al. found significantly higher TID and IDI in
fractured, long-term bisphosphonate treated patients compared to osteoporotic control
patients [30] (Figure 3.14 A and B).
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Figure 3.14 A & B Results of Güerri-Fernández et al. [30]

Aref et al. studied beagles treated with bisphosphonates for 6 months and found a
decrease in IDI and ED when indenting beagle ribs compared ribs taken from untreated
beagles [34].

Discrepancy between the presently observed increases in IDI and ED with

increasing bisphosphonate treatment duration in human bone and the decreased IDI and
ED observed in beagles following 6 months of bisphosphonate treatment may be due to
the single brief treatment duration of the beagle study compared to the lengthy (0.3 to 14
years) treatment durations used in the present study.

Figure 3.15 Comparing control (VEH) and BP treated (RAL) beagle by Aref et al. [34]
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Nogués et al. used a similar RPI device which outputs a different parameter than
the RPI device in the present study [42]. Nevertheless, Nogués et al. found a significant
decrease in the bone material strength index, the single output parameter of their RPI
device, in 40 long-term treated patients treated with bisphosphonates for 4-14 years [42].
Gallant et al. found that healthy beagles treated with bisphosphonates for three years
showed a significant increase in cortical rib IDI compared to untreated control beagles
(Figure 3.16) [35]. Gallant et al. also was able to correlate their IDI results to bone
toughness as measured by three-point bending testing of excised beagle ribs [35].

Figure 3.16 Results of Gallant et al. [35]
3.4.3

Loading/Unloading Slope with Increasing Treatment Duration
The present study showed that RPI parameters involving loading and unloading

portions of the force-depth indentation cycle were related to bisphosphonate treatment
duration. Multiple regression models relating AvgUS, US1st, and AvgLS to treatment
duration, following the inclusion of age and calcium supplementation as covariates, all
showed negative slopes in the expressions relating the dependent variable (RPI
parameters) to the independent variable (treatment duration). Unloading slope, not
loading slope, is traditionally used in other indentation methods to calculate elastic
modulus of a material [22] [23]. Like the RPI indentation depth measurements, the
loading/unloading slope output parameters of the RPI device are indications of wellestablished material properties.
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3.4.4

Loading/Unloading Slope and Material properties
Gallant et al. found significantly lower values of US1st in diabetic rat femurs and

vertebrae compared to a nondiabetic control group [35]. US1st has been associated with
material properties derived from rat vertebral axial compression testing such as toughness
and modulus [35].
3.4.5

Correlated RPI Parameters and Trabecular Bone Mechanical Properties
Studies comparing RPI parameters to traditional mechanical properties the idea

that increases in IDI, TID, and ED and decreases in AvgUS, US1st, and AvgLS indicate a
decrease in a material’s yield stress, strength, and toughness. The presently observed
increases in IDI, TID, and ED with increasing BP treatment duration indicate a decline in
the material properties of trabecular bone with increasing bisphosphonate treatment
duration. If loading and unloading slope RPI parameters (AvgUS, US1st, and AvgLS)
are in fact indicators of modulus and toughness, as found by Gallant et al., then the
present study’s results show a decline in trabecular bone modulus and toughness with
increasing bisphosphonate treatment.
3.5

Uncorrelated RPI Parameters
Three parameters (CID, CID1st, and ID1st) were uncorrelated with

bisphosphonate treatment duration. Two of these parameters, CID and CID1st, are creeprelated and measure changes in probe displacement during constant load application.
This lack of significance may be a result of the selected device loading frequency of 2
Hertz and bone sample preparation. Dehydrated bone is known to have decreased
viscoelastic properties, increased material modulus, and increased microhardness as
measured by nanoindentation [43]. Creep related RPI measurements are less sensitive in
dry bone and thus less able to detect changes associated with bisphosphonate duration.
The length of time in which a constant force is applied before the device takes a creeprelated RPI measurement is short. Specifically, the present study used an indentation
frequency of 2 Hz resulting in a constant force being applied to the sample for 0.167
seconds for each indentation cycle as shown in Figure 3.17. Other nanoindentation
studies using dehydrated cortical bone apply constant load loading for 30 to 60 seconds to
measure material creep properties accurately [50] [44] [45]. Relatively short loading
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durations from the RPI device, and the use of dehydrated bone samples, decreased the
magnitude of RPI creep parameters to the extent that RPI creep parameter magnitudes
were comparable in size to the measurement uncertainty of the RPI device. This
similarity reduced the likelihood of detecting a significant correlation.
The remaining RPI parameter, 1st cycle indentation depth (ID1st), was unrelated
to BP treatment duration even when considering patient age and calcium supplementation
as covariates (p=0.088). The ID1st parameter is directly affected by physical
imperfections in the volume of bone it deforms. The initial indentation produces the
largest plastic deformation of all cycles (Figure 3.18 and Figure 3.19). Therefore first
cycle indentation depth is the RPI parameter most likely to be affected by material
variances within a volume. Even though many of these imperfections are on the level of
nanometers, altering TID a single micron is a 2.2-3.8% measurement variation. For
comparison, a study by Granke, et al. found the variation for TID on a homogeneous,
calibrated surface to be 0.8% [36].

Figure 3.17 Force-Time Graph of a 4 N 5 Cycle Indent at 2 Hz
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Figure 3.18 Indentation Distance per Cycle

Figure 3.19 Distance-Time Graph of a 4 N, 5 Cycle, and 2 Hz RPI
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Figure 3.20 Force-Distance Graph of a 4 N, 5 Cycle, and 2 Hz RPI
3.5.1

Calcium Supplement Usage
Subjects who did not report use of calcium supplements showed greater rates of

change in IDI and TID with bisphosphonate treatment duration compared to subjects who
reported use of calcium supplements. A rigorous comparison cannot be made between
these two populations because the number of patients in the present study not taking a
calcium supplement (7 patients) is substantially less than patients who did (35 patients).
The increased TID and IDI slopes of bisphosphonate treated individuals not taking a
calcium supplement indicates an accelerated decrease in trabecular bone yield stress,
strength, and toughness versus bisphosphonate treated patients taking a calcium
supplement [13]. Alternatively, decreased TID and IDI slopes of bisphosphonate treated
individuals taking a calcium supplement may indicate that calcium supplementation
decreases the rate at which trabecular bone yield stress, strength, and toughness
deteriorates versus bisphosphonate treated patients not taking a calcium supplement [13].
It is also possible that patients not taking a calcium supplement have a higher likelihood
of noncompliant bisphosphonate usage which would result in an accelerated decrease in
trabecular bone property compared to compliant patients [13].
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3.5.2

Limitations
The linear regression of all BioDent parameters with treatment duration showed a

low R-Square value despite significant p values. There is an inherently high variability
between samples based upon unknown contributing factors inherent to cross sectional
studies.
Bone biopsies selected for this test were all supplied by the University of Kentucky
Division of Nephrology bone library. The inclusion and exclusion criteria used to select
samples were based on available patient information. Patient information was not
comprehensive and some data remain unknown. For example, a patient may have
claimed to have exercised regularly but the degree and type of exercise was not noted.
Accuracy of patient reported information is not assured and no guarantees exist that
patients were completely compliant with their BP treatment.
The shape and size of the substrate beneath the exposed surface of the biopsy was
unknown for each indent. Indentations with visual abnormalities or measurements
resembling PMMA were discarded as discussed in section 3.2.4. It is possible that
indents partially interacting with PMMA because of insufficient substrate volume were
analyzed in the results.
4
4.1

Conclusions
Reference Point Indentation of Trabecular Bone
Reference point indentation can be successfully used to quantify relevant material

parameters of trabecular human bone. The protocol developed for RPI study of such
bone, i.e., indents of 4 N and 5 cycles applied to two indentation sites in each of two
randomly chosen trabeculae per each bone sample, was proven feasible and minimizes
data variability when applied to large numbers of bone samples obtained from a diverse
patient population.
4.2

Relevance of Material Property Changes in Trabecular Bone
Increasing bisphosphonate treatment duration is associated with reductions in

trabecular bone modulus, yield stress, strength, and toughness as reflected by RPI related
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parameters. The relevance of these RPI parameters to well established material
parameters of modulus, yield stress, strength, and toughness are supported by previously
published studies. RPI’s ability to indicate material parameters changes may offer new
opportunities for treatment monitoring. These opportunities may lead to new guidelines
for bisphosphonate treatment discontinuance or to assess the effectiveness of other
treatment options to change bone material properties and subsequently the mechanical
load bearing competence of bone.
4.3
4.3.1

Future Directions
Calcium Supplementation
Comparatively higher rates of increase in IDI and TID in patients not reportedly

taking calcium supplements during bisphosphonate treatment indicates that this treatment
group experienced a higher rate of material property deterioration compared to those
taking a calcium supplement as discussed in section 3.5.1. Patients in this study who
reported taking calcium supplements were observed to have comparatively lower rates of
trabecular bone material property deterioration with increasing bisphosphonate treatment
duration as indicated by TID and IDI. Alternatively, it could be inferred that patients
who use a calcium supplement take greater personal responsibility for their bone health
and are more compliant with their bisphosphonate treatment and thus have more
favorable trabecular bone material properties, as indicated by RPI parameters, because
bisphosphonates are efficacious when taken as prescribed. Evaluation of this hypothesis
awaits further study. A larger cross sectional study may provide some clarifying
information that helps reduce data variations due to possible patient noncompliance.
4.3.2

Nanoindentation Comparison
Reference point indentation parameters are relatively unproven in comparison to

established material parameters such as Young’s modulus, yield point, strength, etc. that
are obtained from conventional destructive material testing. All bone samples indented
with the RPI device in the present study have also been indented using a Nanoindenter
XP (MTS Nano Instruments, Oak Ridge, TN) to measure Young’s modulus and
microhardness. The usefulness of one or more of the nine studied RPI parameters will be
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strengthened if correlations are observed between one or more of these parameters and
Young’s modulus or hardness as measured by nanoindentation.
4.3.3

Cortical Bone RPI

The first objective of this study was to pioneer the use of RPI within trabecular bone.
Some trabecular bone biopsies indented in the present study also contain cortical bone
suitable for reference point indentation. Taking RPI measurements of this cortical bone
despite its small sample size is merited given the successful technique development and
significant correlations between 6 of 9 RPI parameters and varying bisphosphonate
treatment. Comparisons between the RPI parameters of different mineralized tissue types
(cortical and trabecular) within the same sample could be investigated.
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Appendices
Appendix A: SAS Output
The SAS System
The GLM Procedure
Dependent Variable: m_IDI IDI
DF Sum of Squares Mean Square F Value Pr > F

Source
Model

3

2.41449600

0.80483200

Error

40

4.62202389

0.11555060

Corrected Total 43

7.03651989

6.97 0.0007

R-Square Coeff Var Root MSE m_IDI Mean
0.343138 8.098986

0.339927

4.197159

Source DF Type I SS Mean Square F Value Pr > F
age

1 0.00425422

0.00425422

0.04 0.8488

calcium

1 1.03566425

1.03566425

8.96 0.0047

dur

1 1.37457753

1.37457753

11.90 0.0013

Source DF Type III SS Mean Square F Value Pr > F
age

1 0.22529821

0.22529821

1.95 0.1703

calcium

1 1.30151527

1.30151527

11.26 0.0017

dur

1 1.37457753

1.37457753

11.90 0.0013

Parameter

Estimate

Standard t Value Pr > |t|
Error

4.906973072 0.44891197

10.93 <.0001

age

-0.009797848 0.00701678

-1.40 0.1703

calcium

-0.451042684 0.13439376

-3.36 0.0017

0.046788057 0.01356552

3.45 0.0013

Intercept

dur
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The SAS System
The GLM Procedure
Dependent Variable: m_AvgLS AvgLS
DF Sum of Squares Mean Square F Value Pr > F

Source
Model

3

0.00056166

0.00018722

Error

40

0.00394800

0.00009870

Corrected Total 43

0.00450966

1.90 0.1456

R-Square Coeff Var Root MSE m_AvgLS Mean
0.124545 4.499545

0.009935

0.220795

Source DF Type I SS Mean Square F Value Pr > F
age

1 0.00001499

0.00001499

0.15 0.6988

calcium

1 0.00013786

0.00013786

1.40 0.2442

dur

1 0.00040880

0.00040880

4.14 0.0485

Source DF Type III SS Mean Square F Value Pr > F
age

1 0.00010495

0.00010495

1.06 0.3087

calcium

1 0.00019324

0.00019324

1.96 0.1695

dur

1 0.00040880

0.00040880

4.14 0.0485

Parameter

Estimate

Standard t Value Pr > |t|
Error

Intercept

0.2077937786 0.01312000

15.84 <.0001

age

0.0002114664 0.00020507

1.03 0.3087

calcium

0.0054959110 0.00392782

1.40 0.1695

dur

-.0008068786 0.00039647

-2.04 0.0485
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The SAS System
The GLM Procedure
Dependent Variable: m_TID TID
DF Sum of Squares Mean Square F Value Pr > F

Source
Model

3

15.59834135

5.19944712

Error

40

64.66728365

1.61668209

Corrected Total 43

80.26562500

3.22 0.0328

R-Square Coeff Var Root MSE m_TID Mean
0.194334 3.077732

1.271488

41.31250

Source DF Type I SS Mean Square F Value Pr > F
age

1 0.84049497

0.84049497

0.52 0.4751

calcium

1 8.09556885

8.09556885

5.01 0.0309

dur

1 6.66227752

6.66227752

4.12 0.0490

Source DF Type III SS Mean Square F Value Pr > F
age

1 3.40899190

3.40899190

2.11 0.1543

calcium

1 9.68907319

9.68907319

5.99 0.0188

dur

1 6.66227752

6.66227752

4.12 0.0490

Parameter

Estimate

Standard t Value Pr > |t|
Error

Intercept

44.09260007 1.67914191

26.26 <.0001

age

-0.03811227 0.02624606

-1.45 0.1543

calcium

-1.23064879 0.50269588

-2.45 0.0188

0.10300582 0.05074143

2.03 0.0490

dur
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The SAS System
The GLM Procedure
Dependent Variable: m_ED ED
DF Sum of Squares Mean Square F Value Pr > F

Source
Model

3

9.77007515

3.25669172

Error

40

59.45110383

1.48627760

Corrected Total 43

69.22117898

2.19 0.1041

R-Square Coeff Var Root MSE m_ED Mean
0.141143 11.97694

1.219130

10.17898

Source DF Type I SS Mean Square F Value Pr > F
age

1 0.00040943

0.00040943

0.00 0.9868

calcium

1 3.22969821

3.22969821

2.17 0.1483

dur

1 6.53996751

6.53996751

4.40 0.0423

Source DF Type III SS Mean Square F Value Pr > F
age

1 0.76817953

0.76817953

0.52 0.4764

calcium

1 4.27814259

4.27814259

2.88 0.0975

dur

1 6.53996751

6.53996751

4.40 0.0423

Parameter

Estimate

Standard t Value Pr > |t|
Error

Intercept

11.38855347 1.60999695

7.07 <.0001

age

-0.01809186 0.02516528

-0.72 0.4764

calcium

-0.81775016 0.48199549

-1.70 0.0975

0.10205592 0.04865196

2.10 0.0423

dur
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The SAS System
The GLM Procedure
Dependent Variable: m_AvgUS AvgUS
DF Sum of Squares Mean Square F Value Pr > F

Source
Model

3

0.00203197

0.00067732

Error

40

0.00899303

0.00022483

Corrected Total 43

0.01102500

3.01 0.0412

R-Square Coeff Var Root MSE m_AvgUS Mean
0.184305 4.798141

0.014994

0.312500

Source DF Type I SS Mean Square F Value Pr > F
age

1 0.00001984

0.00001984

0.09 0.7680

calcium

1 0.00044477

0.00044477

1.98 0.1673

dur

1 0.00156736

0.00156736

6.97 0.0118

Source DF Type III SS Mean Square F Value Pr > F
age

1 0.00028469

0.00028469

1.27 0.2672

calcium

1 0.00064158

0.00064158

2.85 0.0989

dur

1 0.00156736

0.00156736

6.97 0.0118

Parameter

Estimate

Standard t Value Pr > |t|
Error

Intercept

0.2917207094 0.01980150

14.73 <.0001

age

0.0003482896 0.00030951

1.13 0.2672

calcium

0.0100142836 0.00592811

1.69 0.0989

dur

-.0015799204 0.00059838

-2.64 0.0118
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The SAS System
The GLM Procedure
Dependent Variable: m_US1st US1st
DF Sum of Squares Mean Square F Value Pr > F

Source
Model

3

0.00141269

0.00047090

Error

40

0.00899129

0.00022478

Corrected Total 43

0.01040398

2.09 0.1161

R-Square Coeff Var Root MSE m_US1st Mean
0.135784 4.852376

0.014993

0.308977

Source DF Type I SS Mean Square F Value Pr > F
age

1 0.00000435

0.00000435

0.02 0.8901

calcium

1 0.00024540

0.00024540

1.09 0.3024

dur

1 0.00116294

0.00116294

5.17 0.0284

Source DF Type III SS Mean Square F Value Pr > F
age

1 0.00015893

0.00015893

0.71 0.4054

calcium

1 0.00037375

0.00037375

1.66 0.2046

dur

1 0.00116294

0.00116294

5.17 0.0284

Parameter

Estimate

Standard t Value Pr > |t|
Error

Intercept

0.2943424440 0.01979958

14.87 <.0001

age

0.0002602301 0.00030948

0.84 0.4054

calcium

0.0076433972 0.00592753

1.29 0.2046

dur

-.0013609105 0.00059832

-2.27 0.0284
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